Teriparatide (Recombinant Human Parathyroid Hormone)
Osteoporosis at high risk for fracture in postmenopausal women, men with primary or hypogonadal osteoporosis, and men and women with osteoporosis associated with sustained systemic glucocorticoid therapy.
20 mcg daily into the thigh or abdominal wall (for a max. of 2yrs)
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
Parathyroid hormone is involved in the regulation of bone metabolism, renal tubular reabsorption of calcium and phosphate as well as intestinal calcium absorption. It acts through the binding to specific high-affinity cell-surface receptors.
Urolithiasis; the presence of orthostatic hypotension; history of skeletal malignancies; young patients with open epiphyses; patients with Paget‘s disease of bone; it has the potential to cause osteosarcoma.
Allergy to teriparatide or any excipient of the formulation.
Arthralgia; pain; nausea; and mild asymptomatic hypercalcemia.
Drug interactions: Digoxin. Saag et al. (2007) found that among patients with osteoporosis who were at high risk for fracture, bone mineral density increased more in patients receiving teriparatide than in those receiving alendronate.